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PROGRESSIVE NEUROLOGIC DISORDER: INITIAL
MANIFESTATION OF HEMOPHAGOCYTIC
LYMPHOHISTIOCYTOSIS
Hemophagocytic lymphohistiocytosis (HLH) is a syn-
dromeof pathologic immune activationoccurring as a pri-
mary genetic disorder, or in association with infections,
malignancies, or rheumatologic disorders (secondary
HLH).1 CNS inflammation has been observed in both
forms of HLH, but has not been previously reported as
the presenting sole manifestation of the disease.2
Case report. A 14-year-old Caucasian female presented
with a 3-month history of headaches, progressive right-
sided convergent squint, dysarthria, gait abnormality
with progressive difficulty in climbing up the stairs
and being able to stand, and hyperesthesia
involving her left arm and leg. She had a long-
standing history of pervasive refusal disorder for
which she was receiving psychiatric support.
Ophthalmology examination revealed a VI cranial
nerve palsy and papilledema. She had normal tone,
with decreased power in upper and lower limbs
and absent reflexes, and no ankle clonus; there
was no hepatosplenomegaly and no peripheral
lymphadenopathy detected. Brain and spine
MRI revealed leptomeningeal enhancement and
generalized white matter lesions, in addition
to mid–cervical cord contrast-enhancing lesions
(figure, A–D). EMG demonstrated motor and
sensory neuropathy; sural nerve biopsy showed
axonal degeneration with mild inflammatory
changes but no vasculitis. Hemoglobin was 14.7
g/dL (reference range [RR] 12–16 g/dL), platelet
count 261 3 109/L (RR 150–450 3 109/L), white
cell count 5.63 3 103/L (RR 4.0–11.0 3 103/L),
alanine transaminase 17 U/L (RR 10–45 U/L), and
fibrinogen 2.8 g/L (RR 1.7–4.0 g/L); ferritin was
not tested. Oligoclonal bands were positive on
CSF examination, suggesting a CNS inflammatory
process; other extensive investigations excluded
infective, rheumatologic, metabolic, and malignant
causes. She was considered to have an unclassified
neuroinflammatory disease and was treated
empirically with IV immunoglobulin (1 g/kg) and
corticosteroids (IV methylprednisolone at 30 mg/kg
over 3 days and oral prednisolone 2 mg/kg/d tapered
over 8 weeks), with resolution of white matter
lesions and improvement of the dysarthria, squint,
papilledema, headaches, and hyperesthesia, although
her mobility remained impaired despite intense
physiotherapy. Thirteen months later, she developed
a generalized seizure requiring admission to intensive
care, with fever and pancytopenia (hemoglobin at 7.6
g/dL, platelet count 55 3 109/L, and white cell count
3.5 3 103/L). Blood PCR for Epstein-Barr virus was
positive at 850,000 copies/mL. She was thought to have
viral-induced secondary HLH on the background of
a neuroinflammatory syndrome. She was treated with
IV methylprednisolone at 30 mg/kg/d for 3 days, oral
prednisolone 2 mg/kg/d tapered over 4 months,
rituximab (375 mg/m2 weekly for 4 weeks), and
mycophenolate mofetil (1,200 mg/m2/d).
Whole exome sequencing revealed known path-
ogenic compound heterozygous mutations in
UNC13D: exon 10 (c.C817T; p.R273X) and exon
14 (c.G1241T; p.R414L),3,4 confirmed using
Sanger sequencing (figure, E; e-Methods and table
e-1 on the Neurology® Web site at Neurology.org),
Munc 13-4 protein was absent (figure, F), and
defective CD8 T cell degranulation was demon-
strated (figure, G; e-Methods). Based on these re-
sults, the patient was fast-tracked to allogeneic
hematopoietic stem cell transplantation. At the
time of writing, she remains well with no further
hematologic and/or neurologic manifestations of
HLH at 4 months after allogeneic hematopoietic
stem cell transplantation.
Discussion. We report a case of primary HLH that
rather atypically presented with an isolated neuro-
logic disorder. We suggest that HLH should be
included in the differential diagnosis of unclassi-
fied progressive neuroinflammatory disease, even
in the absence of pancytopenia. Functional screen-
ing assays, such as quantification of T and NK cell
degranulation, and intracellular perforin staining,
can be used to promptly identify patients with pri-
mary HLH and guide management.5
Neurologic signs are present in up to 63% of
children with primary HLH at disease onset2; the
majority, however, also have other classic HLH
manifestations. Our patient presented with an
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isolated progressive neurologic disorder, 13 months
before more typical HLH features.2 CNS involve-
ment in HLH can radiologically mimic neuroin-
flammatory disorders including multiple sclerosis
and acute disseminated encephalomyelitis.6 Since
diagnostic delay may result in fatalities or irrevers-
ible neurologic sequelae,2 clinicians should be aware
that unclassified neuroinflammatory diseases could
evolve into full-blown HLH.
This late development of more typical HLH
manifestations in our patient is intriguing. The
heterozygous R414L mutation has been described
in 2 patients with compound heterozygous muta-
tions in UNC13D with late-onset primary HLH
associated with encephalopathy in the context of
other typical features of HLH.3 Patients with at
least one allele bearing a nonsynonymous rather
than a disruptive mutation may develop symptoms
at a significantly older age, suggesting that residual
degranulation function allows some defensive
capacity.7
Our case report also highlights the utility of next-
generation sequencing in making early genetic diag-
noses and enabling targeted treatments.7
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Figure Imaging findings, Sanger sequencing, Munc protein expression, and CD107a degranulation assay in a 14-year-old female with
progressive neurologic disorder due to primary hemophagocytic lymphohistiocytosis
(A) Coronal fluid-attenuated inversion recovery–weighted MRI of the brain, (B) sagittal T2-weighted imaging of the cervicothoracic spine, and (C) axial T2-
weighted imaging of the brain, showing bilateral lesions in the brain (internal capsules, globi pallidi, subthalamic nuclei, deep white matter), as well as mid–
cervical spine lesions. (D) Axial postcontrast T1-weighted imaging at the level of the cerebellum revealed bilateral diffuse leptomeningeal enhancement.
(E) Sanger sequencing chromatogram of UNC13D gene showing compound heterozygous mutations in exon 10 (c.C817T; p.R273X) and exon 14
(c.G1241T; p.R414L) for the same patient. (F) Western blot analysis in patient-derived peripheral blood mononuclear cells shows absence of Munc 13-4
protein relative to a healthy control. (G) Flow cytometric figures show absent percentage increase in CD107a-positive cells in patient-derived CD8 T cells
following stimulation with anti-CD3 antibody in relation to a healthy control.
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THROMBECTOMY RECOVERS AN AORTIC WALL
FRAGMENT FROM MIDDLE CEREBRAL ARTERY
IMMEDIATELY AFTER TAVI
An 80-year-old woman underwent transcatheter aor-
tic valve implantation (TAVI) using an Edward
Sapien S3 device to treat symptomatic severe aortic
stenosis, with a 0.8 cm2 aortic valve area.
After valve implantation, the patient developed sud-
den onset of global aphasia and severe right-sided hemi-
paresis. The instantly performed precontrast cranial
CT scan showed no signs of ischemia, but CT perfu-
sion imaging demonstrated a severe impairment of
blood supply in the left cerebral hemisphere in accor-
dance with the acute clinical symptoms (figure). Fur-
ther CT angiography suggested a middle cerebral artery
(MCA) occlusion. After a brief interdisciplinary evalu-
ation of the case, the patient was rapidly transferred to
the department of neuroradiology, where a conven-
tional angiography confirmed the diagnosis of an acute
MCA occlusion. An immediate thrombectomy (preset
4 3 20 stent retriever and Navien 58 distal-access
catheter) retrieved a solid piece of tissue measuring
2 3 0.5 3 0.1 cm. Neither thrombolysis nor heparin
was administered during mechanical thrombectomy as
the partial thromboplastin time was still elevated to
126 seconds from the recent TAVI procedure. The
clinical symptoms of the patient were relieved directly
after flow restoration to a mild expressive aphasia and
a latent palsy of the right leg. A follow-up cranial CT
scan 3 days later did not detect any ischemic infarction.
Histopathologic examination of the recovered object
demonstrated endothelialized tissue most likely repre-
senting internal parts of an arterial vessel wall with
atherosclerotic changes. Of note, no adjacent thrombus
could be detected in the Elastica-van-Gieson stain (fig-
ure). Echocardiography demonstrated the implanted
aortic valve in place with good function.
Recently, TAVI has become a standard treatment for
elderly patients with severe aortic stenosis and a high sur-
gical risk.1 While clinically manifest strokes as a compli-
cation have been estimated to occur in up to 5% of
TAVI procedures,2 clinically silent cerebral MRI lesions
can be detected in over 80% of cases.3 This is of special
importance as a periprocedural stroke is associated with
both dependency and mortality.4 The use of specific
emboli protection systems may be able to lower the rate
of periprocedural strokes, but needs to be established in
larger case series.5 To our knowledge, no specific treat-
ment guidelines on large periprocedural strokes exist.
Current studies prove mechanical thrombectomy to be
the most effective treatment in patients with thrombo-
embolic proximal artery occlusion.6 We could identify
one previous case report in the literature that describes
a recovery of a soft thrombus by mechanical thrombec-
tomy after TAVI.7 This case report demonstrates for the
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